Shared Resource: Genomic and RNA Profiling

CORE：基因组和RNA分析共享资源(Omics Group) 项目总结 DLDCC基因组和RNA图谱共享资源(GARP SR)满足学术需求 满足癌症中心研究人员的需求，并保持灵活性，以帮助开发新的应用程序。这是一个 与新兴技术和癌症中心不断变化的需求保持同步的动态设施。 DLDCC的调查人员已经能够通过利用国家- 最先进的技术，包括基于微阵列和深度测序的基因组和转录组分析 工具。这项研究涉及异常表达、全基因组表达扰动、或 转录后基因调控。这些工具的范围从全基因组分析到单个基因。 检测和整个组织到单个细胞。一个例子是中等吞吐量多路传输的实现 纳米串计数器数字定量系统等技术，可以分析多达800个多路 分子靶标在非常短的标准化时间内。这个平台帮助癌症中心的研究人员 远离全基因组筛查或从Illumina测序中识别基因签名的人 现在关注的是可能预测癌症进展的标志性基因或途径集。这些 然后，签名可以用来开发和测试旨在干扰特定基因的新药 产物或信号通路。GARP SR努力找到正确的工具来帮助癌症中心调查人员 把癌症理解为一种复杂的疾病。我们帮助了许多研究人员从BASIC 研究翻译研究，努力将他们的发现带到临床，通过提供访问 新技术。有大量的DLDCC研究人员需要 利用这一资源开展他们的研究。基因组图谱实验的成本可能令人望而却步 无法访问共享资源的个人调查员。数据分析需要有统计和分析经验 生物信息学和这个资源将为DLDCC提供坚实基础的个人群体聚集在一起 研究人员将使他们能够成功地利用基因组技术--这是不可能的 在没有这种共享资源的情况下是可能的。

CORE: Genomic and RNA Profiling Shared Resource (Omics Group) PROJECT SUMMARY The Genomic and RNA Profiling Shared Resource (GARP SR) of the DLDCC works to meet the academic needs of cancer center investigators and remain flexible to aid in developing new applications. This is a dynamic facility that has kept pace with emerging technologies and the changing needs of the cancer center. DLDCC investigators have been able to make significant advancements in cancer research by utilizing state- of-the-art technologies including microarray- and deep sequencing-based genomic and transcriptomic analysis tools. This research has involved studies of aberrant expression, genome wide-perturbations of expression, or post transcriptional gene regulation. These tools range from whole genome wide assays to individual gene assays and whole tissue to single cell. An example is the implementation of medium throughput multiplexing technologies such as the NanoString nCounter digital quantitation system that can assay up to 800 multiplexed molecular targets in a very short, standardized time. This platform helps cancer center investigators who are moving away from genome-wide screening or who identify a gene signature from Illumina sequencing and are now focusing on the signature sets of genes or pathways that may predict cancer progression. These signatures could then be used to develop and test novel drugs designed to interfere with specific gene products or signaling pathways. GARP SR strives to find the right tools to help cancer center investigators to understand cancer as a complex disease. We have aided many researchers in a transition from basic research into translational research in an effort to bring their discoveries to the clinic by providing access to new technologies. There are a large number of DLDCC researchers who require the methodologies offered in this resource to carry out their studies. Costs for genomic profiling experimentation can be prohibitive to the individual investigator without access to a shared resource. Data analysis requires experience in statistics and bioinformatics and this resource brings together groups of individuals who provide a solid base for DLDCC researchers that will enable them to successfully utilize genomic technology—something that would not be possible without this shared resource.